Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients

被引：0

作者：

Olanow, C. Warren ^{[1
]}

Stocchi, Fabrizio ^{[2
,3
]}

Poewe, Werner ^{[4
]}

Ellenbogen, Aaron ^{[5
,6
]}

Djaldetti, Ruth ^{[7
]}

Minei, Tami Rachmilewitz ^{[8
]}

Cohen, Yael ^{[8
]}

Oren, Sheila ^{[8
]}

Kieburtz, Karl ^{[9
]}

机构：

[1] Mt Sinai Med Ctr, New York, NY 10029 USA

[2] Univ Rome, Rome, Italy

[3] IRCCS San Raffaele Roma, Rome, Italy

[4] Univ Hosp Neurol, Innsbruck, Austria

[5] Michigan Inst Neurol Disorders, Farmington Hills, CT USA

[6] Quest Res Inst, Farmington Hills, CT USA

[7] Tel Aviv Univ, Petah Tiqwa, Israel

[8] NeuroDerm, Rehovot, Israel

[9] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

来源：

NEUROLOGY | 2018年 / 90卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S26.003

引用

页数：3

共 27 条

[1] A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients
Kieburtz, K.
Olanow, C. W.
Cohen, Y.
Oren, S.
MOVEMENT DISORDERS, 2016, 31 : S648 - S648
[2] Pharmacokinetic and safety characterisation of carbidopa/levodopa subcutaneous infusion (ND0612): Phase I studies in healthy volunteers and patients with fluctuating Parkinson's disease
Lewitt, P.
Caraco, Y.
Adar, L.
Oren, S.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 514 - 514
[3] Pharmacokinetic profile of ND0612L (levodopa/carbidopa for subcutaneous infusion) in patients with moderate to severe Parkinson's disease
Giladi, N.
Caraco, Y.
Gurevich, T.
Djaldetti, R.
Cohen, Y.
Yacobi-Zeevi, O.
Oren, S.
MOVEMENT DISORDERS, 2015, 30 : S87 - S88
[4] Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of Parkinson's disease (PD) and Experiences of Daily Living
Rascol, O.
Isaacson, S.
LeWitt, P.
Poewe, W.
Ferreira, J.
Lopes, N.
Sopromadze, S.
Pereira, J.
Olanow, C.
MOVEMENT DISORDERS, 2024, 39 : S313 - S313
[5] Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD
Olanow, W.
Ellenbogen, A.
Djaldetti, R.
Minei, T. Rachmilewitz
Cohen, Y.
Oren, S.
Kieburtz, K.
MOVEMENT DISORDERS, 2017, 32
[6] Enrolment characteristics for patients entering a Phase 3 study of subcutaneous levodopa/carbidopa infusion with ND0612
Rascol, O.
Albanese, A.
Ellenbogen, A.
Ferreira, J.
Gurevich, T.
Hassin, S.
Hernandez-Vara, J.
Isaacson, S.
Kieburtz, K.
LeWitt, P.
Manzanares, L. Lopez
Olanow, C.
Pahwa, R.
Poewe, W.
Sarva, H.
Stocchi, F.
Yardeni, T.
Adar, L.
Salin, L.
Lopes, N.
Sasson, N.
Case, R.
Espay, A.
Giladi, N.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 708 - 709
[7] Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson's disease (PD)
Espay, A.
Pahwa, R.
Ellenbogen, A.
Stocchi, F.
Giladi, N.
Salin, L.
Sasson, N.
Pereira, J.
Rascol, O.
MOVEMENT DISORDERS, 2024, 39 : S301 - S301
[8] ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
Giladi, N.
Caraco, Y.
Gurevich, T.
Djaldetti, R.
Adar, L.
Minei, T. Rachmilewitz
Oren, S.
MOVEMENT DISORDERS, 2017, 32
[9] Improvement of individual quality of life in caregivers and patients under L-dopa/carbidopa duodenal infusion therapy
Ehlers, C.
Honig, H.
Odin, P.
MOVEMENT DISORDERS, 2015, 30 : S541 - S542
[10] Pharmacokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson's disease (PD) patients with motor fluctuations: results of a phase IIa dose finding study
Giladi, N.
Caraco, Y.
Gurevich, T.
Djaldetti, R.
Cohen, Y.
Yacobi-Zeevi, O.
Oren, S.
Kieburtz, K.
Olanow, C. W.
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 66 - 66

← 1 2 3 →